Another current phase I/II clinical trial, the KOMET-001 trial (NCT04067336), is investigating ziftomenib (KO-539) in patients with R/R AML with KMT2A-r or NPM1 mutations. The gene discussed is NPM1; the disease is acute myeloid leukemia.